Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus

Completed · Phase 1 · Has a placebo group

Conditions studied: Marburg Hemorrhagic Fever

In brief

The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-6003, a post-exposure prophylaxis candidate treatment for Marburg virus.

Key facts

Study ID

NCT01353040

Run by

Sarepta Therapeutics, Inc.

People needed

30

Starts

2011-05-01

Expected to finish

2011-12-01

Last updated by the study team

2012-05-07

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female and between the ages of 18 and 50 years in good general health
• Volunteers must be willing to use barrier methods of contraception or be of non-childbearing potential
• Volunteers must be willing to undergo a urine screen for drugs of abuse

You may not qualify if…

• Pregnancy or breastfeeding.
• Any clinically relevant abnormalities in physical examinations, vital signs, ECG, clinical chemistry, hematology or urinalysis
• Positive test for human immunodeficiency virus, hepatitis B or hepatitis C or known history of HIV infection

Where it is running

• West Coast Clinical Trials — Cypress, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.